Multiply-resistant Pseudomonas aeruginosa were first detected in north-eastern Germany at the end of 1996; since then they have been isolated predominantly from patients in intensive care units. Colonization/infection, especially of the respiratory tract, has been demonstrated in 80 patients, with strains resistant to -lactams, carbapenems, aminoglycosides and quinolones. Amikacin showed in-vitro synergy with cefepime, ceftazidime or piperacillin/tazobactam. Horizontal transfer of strains was followed by PFGE and identical strains were detected in the environment, but the source of infection was not established. Rigorous infection control and restricted clinical use of carbapenems limited further dissemination of this outbreak.
Introduction
Pseudomonas aeruginosa is one of the commonest nosocomial pathogens in intensive care units (ICUs). It is intrinsically resistant to a number of structurally unrelated antimicrobial agents, and its resistance to other agents is increasing. During the course of 15 months we followed the circulation of multiply-and highly-resistant P. aeruginosa in different ICUs within the University hospital in Greifswald. Clinical isolates were investigated by phenotyping and genotyping and compared with strains isolated from the environment.
Materials and methods

Patients and specimens
Between December 1996 and May 1998, multiply-resistant strains of P. aeruginosa were isolated from routine clinical specimens (tracheal secretions, blood, venous catheter and urine) from 80 ICU patients.
Strains and antimicrobial testing
Primary isolation was performed on Columbia agar containing 5% sheep blood. Antibiotic susceptibility was determined using Mueller-Hinton agar by a disc diffusion method with the following discs (Becton Dickinson GmbH, Heidelberg, Germany): ceftazidime (30 g), cefsulodine (30 g), cefepime (30 g), azlocillin (30 g), piperacillin/ tazobactam (30 g/10 g), imipenem (10 g), meropenem (10 g), gentamicin (10 g), tobramycin (10 g), amikacin (30 g), ciprofloxacin (5 g), ofloxacin (5 g), aztreonam (30 g) and polymyxin B (300 g).
Susceptibility, resistance and moderate susceptibility were defined by the criteria of Deutsches Institut für Normung e.V. (DIN). 1 For selected strains (isolates from the beginning of the outbreak and 15 months later) MIC values were determined by the Etest (AB Biodisk, Solna, Sweden).
Screening tests for synergy were performed by a simplified disc method. When positive results were obtained, further tests were performed using a combination of agar dilution and agar diffusion test. 2 
Serotyping
The O serotype was determined using a slide agglutination test with a set of four pools (OMA, OMC, OME, OMF) and 16 monovalent antisera numbered O1 to O16 (Sanofi Diagnostics Pasteur GmbH, Freiburg, Germany).
Genotyping
The genetic relationship of strains with identical multiresistance patterns was investigated by pulsed-field gel electrophoresis (PFGE) using a Gene Path Group 3 Kit 
Results
Colonization/infection with multiresistant P. aeruginosa strains was observed in 80 patients. The specimens from which multiresistant P. aeruginosa strains were isolated most frequently were tracheal secretions, blood, urine and surgical wound swabs. All strains were resistant to -lactams (ceftazidime, cefepime, cefsulodine, azlocillin and piperacillin/tazobactam), including carbapenems (imipenem, meropenem) and aztreonam, and to aminoglycosides (amikacin, tobramycin, gentamicin) and quinolones (ciprofloxacin, ofloxacin). Only polymyxin B demonstrated in-vitro activity. Agar diffusion tests were confirmed by Etest. Multiple resistance was usually associated with high-level resistance (Table I) .
In-vitro synergy was detected between amikacin and the following antibiotics: cefepime, ceftazidime and piperacillin/tazobactam; there was no synergy between amikacin and imipenem, nor between gentamicin or tobramycin in combination with -lactams. The combinations that showed synergy in the primary screening were tested further using the agar dilution-agar diffusion test. The best results were obtained with the combination of amikacin and cefepime, independent of which agents were used in the agar dilution (Table II) .
Multiply-resistant strains of P. aeruginosa were isolated from the environment (basins and showers) and in the rinsing water of a manually prepared bronchoscope. Swabs collected from medical staff (hands, nose and throat) were consistently negative.
The results of serotyping were ambigious. Weak agglutination was obtained with the serum pool OME. After several passages over cetrimide agar this agglutination became stronger, but examination of the monovalent anti-O sera contained in this pool (O2, O5, O15 and O16) did not confirm a serotype. PFGE showed that isolates from patients and those from the environment were genetically identical or closely related (Figure) .
Discussion
Resistance of P. aeruginosa to multiple antimicrobial agents is often associated with the production of extended spectrum mutants of the class D -lactamases, OXA-2 and OXA-10, 3-5 as OXA-11, -14, -15, -16, -17 and -18. 6 Alterations of outer membrane permeability and changes in the active efflux systems can also influence sensitivity to antibiotics. 7 Moderate resistance of P. aeruginosa to imipenem usually results from modification of OprD protein expression or loss of D2 porin. [8] [9] [10] MICs of about 8 mg/L are typical for this mechanism of resistance. The underlying mechanism of imipenem resistance in our strains cannot be explained simply by alteration of this outer membrane protein, because the MICs were higher (Ͼ32 mg/L). It may be that several factors gave rise to resistance to all the -lactams, including carbapenems, but the expression of a metallo--lactamase gene of the IMP1 type, first detected in P. aeruginosa strains in Japan, 10 must be assumed. Trials to investigate whether this hydrolytic activity was present in our strains are under way.
416
Our results concerning the synergic in-vitro interactions of ceftazidime and amikacin correspond to the studies of Giamarellos-Bourboulis et al. 7 The detection of a new group of -lactamases that hydrolyse carbapenems and other broad-spectrum -lactams has led to a new therapeutic strategy in our hospital. Restricted clinical use of broad-spectrum -lactams, including carbapenems, and a rigorous hygienic regime are the most important measures to prevent the spread of the metallo--lactamase gene in P. aeruginosa and other Gram-negative bacilli. Enlargement of the amikacin inhibition zone relative to the control was taken as an indication of synergy. a For patient 11 the MICs measured by Etest were 24 mg/L for cefepime and 96 mg/L for amikacin (Table I) . 
